Hodgkin lymphoma (Hodgkin's Disease) is a malignant neoplasm of young adults, in which immune T-lymphocytes surround the malignant Reed-Sternberg and Hodgkin cells in an apparent natural immune reaction. Since these findings have been appreciated, the therapy of Hodgkin lymphoma now includes surgery, radiotherapy, chemotherapy, T-lymphocyte immunotherapy, and stem-cell transplantation therapy.

Frenster JH, Papalian MM, Masek MA and Frenster JA, "Electron Microscopic Analysis of Lymph Node Cellular Activity in Hodgkin's Disease", Journal of the National Cancer Institute, Vol. 63, pp. 331-335, Aug. 1979.

1. Meisner LF, and Frenster JH, "In-Vivo Evolution within Radiation-Induced Clones of Human Lymphocytes", J. Cell Biol. vol. 39, part 2, p. 155a (1968).

2. Archibald RB, and Frenster JH, "Quantitative Electron Microscopic Sector Analysis of Lymphocyte
Interactions with Reed-Sternberg Cells in Hodgkin's Disease", Proc. Am. Assoc. Cancer Res. 12: 43-44 (1971).

3. Frenster JH, "Electron Microscopic Localization of Acridine Orange Binding to DNA within Human Leukemic Bone Marrow Cells", Cancer Res. 31: 1128-1133 (1971).

4. Archibald RB, and Frenster JH, "Quantitative Ultrastructural Analysis of In-Vivo Lymphocyte - Reed-Sternberg Cell Interactions in Hodgkin's Disease", Natl. Cancer Inst. Monogr. 36: 239-245 (1973).

5. Masek MA, Rhoades DJ, and Frenster JH, "In-Vivo Macrophage Interactions with Lymphocytes in Hodgkin's Disease", Proc. Am. Assoc. Cancer Res. 14: 8 (1973).

6. Frenster JH,  and Herstein PR, "Gene De-Repression", New Eng. J. Med. 288: 1224-1229 (June 7, 1973).

7. Frenster JH, Nakatsu SL, and Masek MA, "Ultrastructural Probes of DNA Templates within Human Bone Marrow and Lymph Node Cells", Adv. Cell Molec. Biol. 3, 1-19 (1974).

8. Frenster JH, "Ultrastuctural Probes of Gene De-Repression within Human Leukemia and Lymphoma Cells", Proc. 11th International Cancer Congress, Florence, Italy (October, 1974).

9. Rowan RA, Masek MA, Thompson JM, and Frenster JH, "Electron Microscopic Localization of Acid Phosphatase Activity within Hodgkin's Disease Lymph Nodes", Proc. Am. Assoc. Cancer Res. 16: 10 (1975).

10. Frenster JH, "Analysis of Queueing and Renewal Systems in Hodgkin's Disease", Proc. Am. Assoc. Cancer Res. vol. 16: p. 223 (March, 1975).

11. Frenster JH, Landrum SR, Masek MA, and Wilson LS, "Nuclear Maturation Within Neoplastic Cells In-Vivo", J. Cell Biol. 67: 123a (1975).

12. Frenster JH, Landrum SR, Masek MA, et al, "Comparison of DNA Helix Openings during In-Vivo Mitosis of Normal and Neoplastic Human Cells", Proc. Am. Assoc. Cancer Res. 19, 1-2 (1978).

13. Frenster JA, Papalian MM, Masek MA, et al, "Persistent Euchromatin after DNA Template Inactivation", J. Cell Biol. 79, 110a-111a (1978).

14. Frenster JH, Papalian MM, Masek MA, and Frenster JA, "Asymmetry of Intra-Nuclear Function during Immune Lymphocyte Activation", Biophys. J. vol. 25, no. 2, part 2, p. 228a, Feb. 1979.

15. Frenster JH, Papalian MM, Masek MA and Frenster JA, "Electron Microscopic Analysis of Lymph Node Cellular Activity in Hodgkin's Disease", Journal of the National Cancer Institute, Vol. 63, pp. 331-335, Aug. 1979.

16. Frenster JH, "Single-Cell Analysis of DNase I-Sensitive Sites During Neoplastic Cell Differentiation within Hodgkin's Disease Lymph Nodes", Leukemia Reviews International, Rich MA, Editor, Volume 1, pp. 22-23, (Marcel Dekker, Inc. New York/1983).

17. Frenster JH, "Single-Cell Analysis of DNase I-Sensitive Sites during Neoplastic and Normal Cell Differentiation within Human Bone Marrow", Ann. N.Y. Acad. Sci. 567: 334-336 (Aug. 4, 1989).

18. Ruf IK, Rhyne PW, Yang C, Cleveland JL, and Sample JT, "Epstein-Barr Virus Small RNAs Potentiate Tumorigenicity of Burkitt Lymphoma Cells Independently of an Effect on Apoptosis", J. Virol. vol. 74, no. 21, pp. 10223-10228 (November, 2000).

19. Maruo S, Nanbo A, and Takada K, "Replacement of the Epstein-Barr Virus Plasmid with the EBER Plasmid in Burkitt's Lymphoma Cells", J. Virol. vol. 75, no. 20, pp. 9977-9982 (October, 2001).

20. Frenster JH, "Uni-Polar Clustering of Lymphocyte DNA Templates Toward Neoplastic Target Cells within Hodgkin's Disease Lymph Nodes", Proc. Am. Assoc. Cancer Res. vol. 43, p. 1134 (March, 2002).

21. Carella AM, "Stem Cell Transplantation for Hodgkin's Disease: A Review of the Literature", Clinical Lymphoma, vol. 2, no. 4, pp. 212-221 (March, 2002).

22. Childs RW, "Immunotherapy of Solid Tumors: Nonmyeloablative Allogeneic Stem Cell Transplantation", Advances in Cancer Treatment Newsletter, Medscape Hematology-Oncology eJournal 5(3), June, 2002.

23. Faulkner RD, Craddock C, Byrne JL, Mahendra P, Haynes AP, Prentice HG, Potter M, Pagliuca A, Ho A, Devereux S, McQuaker G, Mufti G, Yin JL, and Russell NH, "BEAM-Campath reduced intensity allogeneic stem cell transplantation for lymphoproliferative disease: GVHD, toxicity and survival in 65 patients". Blood First Edition Paper, prepublished online September 11, 2003; DOI 10.1182/blood-2003-05-1406.

24. Coughlin CM, Vance BA, Grupp SA, and Vonderheide RH, "RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy", Blood First Edition Paper, prepublished online November 20, 2003;
DOI 10.1182/blood-2003-07-2379.

25. Murray PG, Qiu G-H, Fu L, Waites ER, Srivastava G, Heys D, Agathanggelou A, Latif F, Grundy RG, Mann JR, Starczynski J, Crocker J, Parkes SE, Ambinder RF, Young LS, and Tao Q, "Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma", Oncogene, vol. 23, no. 6, pp. 1326-1331 (February 2, 2004).

26. Su C-C, Chiu H-H, Chang C-C, Chen J-C, and Hsu S-M, "CD30 is Involved in Inhibition of T-Cell Proliferation by Hodgkin's Reed-Sternberg Cells", Cancer Research, vol. 64, no. 6, pp. 2148-2152 (March 15, 2004).

27. Mathas S, Lietz A, Anagnostopoulos I, Hummel F, Wiesner B, Janz M, Jundt F, Hirsch B, Jöhrens-Leder K, Vornlocher H-P, Bommert K, Stein H, and Dörken B, "c-FLIP Mediates Resistance of Hodgkin/Reed-Sternberg Cells to Death Receptor–induced Apoptosis",  J. Exp. Med., vol. 199, no. 8, pp. 1041-1052 (April 19, 2004).

28. Dutton A, O'Neil JD, Milner AE, Reynolds GM, Starczynski J, Crocker J, Young LS,  and Murray PG, "Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death",  Proc. Natl. Acad. Sci. USA, vol. 101, no. 17, pp. 6611-6616 (April 27, 2004).

29. Riddell SR,  "Finding a Place for Tumor-specific T Cells in Targeted Cancer Therapy",
     J. Exp. Med. 2004 200: 1533-1537.

30. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, and Heslop HE, "Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease",  J. Exp. Med. 2004 200: 1623-1633.

31. Relógio A, Ben-Dov C, Baum M, Ruggiu M, Gemund C, Benes V, Darnell RB, and Valcárcel J, "Alternative Splicing Microarrays Reveal Functional Expression of Neuron-specific Regulators in Hodgkin Lymphoma Cells", J. Biol. Chem. vol. 280, no. 6, pp. 4779-4784 (February 11, 2005).

32. Chen JJW, Lin Y-C, Yao P-L, Yuan A, Chen H-Y, Shun C-T, Tsai M-F, Chen C-H, Yang P-C, "Tumor-Associated Macrophages: The Double-Edged Sword in Cancer Progression", Journal of Clinical Oncology, vol. 23, no. 5, pp. 953-964 (February 10, 2005).

33. Re D, Thomas RK, Behringer K, and Diehl V, "From Hodgkin's disease to Hodgkin lymphoma: biological insights and therapeutic potential", Published in Blood First Edition Paper, prepublished online February 22, 2005; DOI10.1182/blood-2004-12-4750.

34. Majhail NS, Weisdorf DJ, Wagner JE, Defor TE, Brunstein CG, and Burns LJ,
"Comparable results of umbilical cord blood and HLA matched sibling donor hematopoietic stem cell transplant after reduced-intensity preparative regimen for advanced Hodgkin's lymphoma".  Blood vol. 107, no. 9, pp. 3804-3807 (May 1, 2006).

35. Janz M, Hummel M, Truss M, Wollert-Wulf B, Mathas S, Johrens K, Hagemeier C, Bommert K, Stein H, Dorken B, and Bargou RC, "Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells", Blood, vol. 107, no. 6, pp. 2536-2539 (March 15, 2006).
 

Additional References:

1. Frenster JH, and Hovsepian JA, "Overshoot in Late Telophase for RNA Re-Programming of Mitotic Chromatin".

2. Hovsepian JA, and Frenster JH, "RNA-Induced Melting of DNA during Selective Gene Transcription".

3. Saha S, Ansari AZ, Jarell KA, and Ptashne M, "RNA Sequences that Work as Transcriptional Activating Regions".

4. Gottesfeld JM,  and Barbas CF III, "RNA as a Transcriptional Activator".

5. Frenster JH, "Ultrastructural Probes of Active DNA Sites, and the RNA Activators of DNA".
 


Top of Page - Euchromatin Network - Current Research - Forums - Other Sites - Future Events -

For Further Information or Feedback:
e-mail:   frenster@euchromatin.net
Phone:   +1 650 367 6483
Fax:   +1 650 364 1773

euchromatin:  "the most active portion of the genome within the cell nucleus".